This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00073/identifier/drugbank/
dctermshttp://purl.org/dc/terms/
n27http://linked.opendata.cz/resource/AHFS/
n12http://linked.opendata.cz/resource/mesh/concept/
n25http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00073/identifier/national-drug-code-directory/
n26http://linked.opendata.cz/resource/drugbank/dosage/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00073/identifier/genbank/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00073/identifier/uniprotkb/
n9http://www.rxlist.com/cgi/generic/
n10http://linked.opendata.cz/resource/drugbank/patent/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00073/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n24http://linked.opendata.cz/resource/drugbank/medicinal-product/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00073/identifier/pharmgkb/
n11http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n16http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/atc/
n22http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00073
rdf:type
n3:Drug
n3:description
Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids
n3:dosage
n26:271B4370-363D-11E5-9242-09173F13E4C5 n26:271B4371-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9704735 # Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004 Jun 17;350(25):2572-81. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15201414 # Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 2005 Apr;78(4):275-80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15795920 # Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M: The epitope recognized by rituximab. Blood. 2006 Sep 15;108(6):1975-8. Epub 2006 May 16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16705086 # Burton C, Kaczmarski R, Jan-Mohamed R: Interstitial pneumonitis related to rituximab therapy. N Engl J Med. 2003 Jun 26;348(26):2690-1; discussion 2690-1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12826649 # http://www.google.com/patents/EP2231183A2?cl=en # http://planetorbitrap.com/data/uploads/528fce2e395be.pdf
n3:group
approved
n3:halfLife
0.8 hours (mammalian reticulocytes, in vitro)
n3:indication
For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
n3:manufacturer
n25:271B436D-363D-11E5-9242-09173F13E4C5
owl:sameAs
n14:DB00073 n15:DB00073
dcterms:title
Rituximab
adms:identifier
n6:Rituximab n17:PA451261 n18:P01857 n19:J00228 n20:50242-053-06 n21:DB00073
n3:mechanismOfAction
The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis.
n3:packager
n25:271B436B-363D-11E5-9242-09173F13E4C5 n25:271B436C-363D-11E5-9242-09173F13E4C5 n25:271B436A-363D-11E5-9242-09173F13E4C5
n3:patent
n10:2149329 n10:5736137 n10:1336826
n3:synonym
AntiCD20 Ig gamma-1 chain C region
n3:volumeOfDistribution
* 3.1 L
n22:hasAHFSCode
n27:10-00-00
n11:hasConcept
n12:M0244307
foaf:page
n9:ritux.htm n16:rituximab.html
n3:Molecular-Formula
n4:271B4376-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4375-363D-11E5-9242-09173F13E4C5
n22:hasATCCode
n23:L01XC02
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
174722-31-7
n3:category
n3:clearance
* 0.34 L/day [RA patients]
n3:containedIn
n24:271B436E-363D-11E5-9242-09173F13E4C5 n24:271B436F-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n4:271B4373-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n4:271B4374-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4372-363D-11E5-9242-09173F13E4C5